Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections†
AbstractWhile 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
De Clercq, E.; Férir, G.; Kaptein, S.; Neyts, J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses 2010, 2, 1279-1305.
De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses. 2010; 2(6):1279-1305.Chicago/Turabian Style
De Clercq, Erik; Férir, Geoffrey; Kaptein, Suzanne; Neyts, Johan. 2010. "Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections." Viruses 2, no. 6: 1279-1305.